Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Jan-Dec:53:19160216241293633.
doi: 10.1177/19160216241293633.

Upfront Surgery Versus Upfront Concurrent Chemoradiotherapy as Primary Modality in Hypopharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Tsung-You Tsai  1 , Wing-Keen Yap  2 , Ting-Hao Wang  1   3 , Yi-An Lu  1 , Anna See  1   4 , Yu-Feng Hu  1 , Yenlin Huang  5   6   7 , Huang-Kai Kao  3   8 , Kai-Ping Chang  1   3
Affiliations
Meta-Analysis

Upfront Surgery Versus Upfront Concurrent Chemoradiotherapy as Primary Modality in Hypopharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Tsung-You Tsai et al. J Otolaryngol Head Neck Surg. 2024 Jan-Dec.

Abstract

Importance: The management of hypopharyngeal squamous cell carcinoma (HPSCC) continues to be one of the most formidable challenges in the realm of head and neck oncology.

Objectives: The aim of this meta-analysis was to evaluate the disparity in survival outcomes between upfront surgery and upfront concurrent chemoradiotherapy as the primary treatment modality in patients with HPSCC.

Design: Systemic review with meta-analysis.

Setting: The meta-analysis was conducted in strict accordance with the PRISMA guideline. A literature search through PubMed, EMBASE, and the Cochrane Library were conducted until January 2023. The adjusted hazard ratio (aHR) with 95% confidence intervals (CIs) of different survival outcomes were extracted and pooled.

Participants: Studies that incorporated HPSCC patients without receiving induction chemotherapy.

Interventions: Upfront surgery versus upfront concurrent chemoradiotherapy.

Main outcome measures: Overall survival (OS) and disease-free survival (DFS).

Results: Eight studies published between 2015 and 2023, with a pooled patient population of 1619, were included in this meta-analysis. The outcomes reveal that upfront surgery was notably linked with improved OS (aHR 0.66, 95% CI 0.57-0.78) and DFS (aHR 0.75, 95% CI 0.63-0.90). Subgroup analyses were conducted to investigate the impact of the overall stage of the tumor and the extent of surgery on OS. In patients with advanced HPSCC (stages III and IV), upfront surgery remained associated with better OS (aHR 0.65, 95% CI 0.56-0.77). Concerning the extent of surgery, both subgroups exhibited a superior OS outcome associated with upfront surgery (exclusive total laryngopharyngectomy group: aHR 0.54, 95% CI 0.39-0.75; total/partial laryngopharyngectomy group: aHR 0.71, 95% CI 0.59-0.84).

Conclusions and relevance: The results demonstrated that upfront surgery showed better OS and DFS than concurrent chemoradiation and remind the clinicians of the potential reduction in survival outcomes when choosing concurrent chemoradiotherapy as primary treatment.

Keywords: CRT; HPSCC; chemoradiotherapy; hypopharyngeal cancer; squamous cell carcinoma; upfront surgery.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Graphical abstract
Graphical abstract
Figure 1.
Figure 1.
PRISMA flow diagram.
Figure 2.
Figure 2.
Quality assessment of included studies by NOS. NOS, Newcastle-Ottawa Scale.
Figure 3.
Figure 3.
Forest plot of the meta-analysis regarding (A) OS and (B) DFS. A random-effects model was applied. OS, overall survival; DFS, disease-free survival.
Figure 4.
Figure 4.
Subgroup analyses on OS (A) grouped by overall stage and (B) grouped by the extent of surgery. A random-effects model was applied. OS, overall survival; TLP, total laryngopharyngectomy; PLP, partial laryngopharyngectomy.
Figure 5.
Figure 5.
Sensitivity analysis for different treatment on OS analysis. OS, overall survival.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Hall SF, Groome PA, Irish J, O’Sullivan B. The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope. 2008;118(8):1362-1371. doi:10.1097/MLG.0b013e318173dc4a - DOI - PubMed
    1. Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462-1475. doi:10.1016/j.annonc.2020.07.011 - DOI - PubMed
    1. National Comprehensive Cancer Network. Head and Neck Cancers (Version 2.2023). Accessed August 25, 2023. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
    1. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88(13):890-899. doi:10.1093/jnci/88.13.890 - DOI - PubMed

MeSH terms

LinkOut - more resources